Reckitt Benckiser Group PLC
http://www.rb.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Reckitt Benckiser Group PLC
Fast Start To Oral Phenylephrine Efficacy Complaints As US FDA Considers 'Any Action'
Two days after FDA advisory panel’s meeting to discuss whether oral phenylephrine is effective for nasal congestion, complaints filed in federal court in multiple states alleging manufacturers knowingly misled public about ingredient’s efficacy. FDA’s potential response to NDAC’S finding wouldn’t come as soon.
Abbott Stops Using ‘#1 Infant Formula Brand’ Claim After Finding Supporting Data Out Of Date
Mead Johnson not only gains with Abbott stopping use of claim on Similac packaging, but also continues using similar claim on Enfamil packages, “#1 Pediatrician Recommended Brand.” In NAD report, Abbott says data backing up its claim apparently wasn’t current.
Haleon’s ‘#1 Doctor Recommended’ Voltaren Claim Challenged By RB Clears NAD Review With Caveat
NAD says in advertising without references to arthritis, Haleon should ensure claim Reckitt challenged “clearly and conspicuously discloses that Voltaren is approved for the treatment of arthritis pain.” Haleon supports “#1 Doctor Recommended” and “#1 Topical Pain Reliever Globally” claims.
Vagisil Marketer Combe Enters Personal Lubricant Market With BioFilm Acquisition
Vagisil and BioFilm’s Astroglide “demonstrate very high levels of brand awareness, brand loyalty, and repeat purchase, and continue to attract new and younger consumers into the category,” firms say.
Company Information
- Industry
- Diversified
-
Pharmaceuticals
- OTC, Consumer
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice